Vaccine Electronic Safety Reporting Guidelines Follow Drug Model
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA draft guidance explains procedures sponsors should use for electronic submissions to the Vaccine Adverse Event Reporting System when new requirements take effect in June 2015.
You may also be interested in...
FDA Adverse Event Reporting Reg Offers Few Exceptions
Companies must submit post-market safety reports electronically beginning in June 2015; waivers will be allowed, but they would only be temporary.
Drug Shortages, Inspections In Focus At US FDA Appropriations Hearing
Commissioner Robert Califf discussed the agency’s request for $12.3m to address shortages and legislation to require that manufacturers provide more detailed information about increased demand and supply chain vulnerabilities.
Clinical Trial Diversity Requires Sponsors Work With An Assortment Of Patient Advocates, Community Organizations
US FDA oncology officials are concerned that the entities sponsors are consulting in developing and implementing clinical trial diversity plans are not sufficiently diverse themselves and do not represent patients in underserved communities.